Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 84

2 391 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 391
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 391 trials in Milan

Open in trial search

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Ovarian cancer

Not yet recruiting

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Autoimmune hepatitis

Not yet recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Asthma

Not yet recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cushing's syndrome

Not yet recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Metastatic renal cell carcinoma

Not yet recruiting

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.